Palvella Therapeutics (PVLA) Could Be 45% Undervalued Following Fresh QTORIN Updates

Palvella Therapeutics (PVLA) has been active on the medical conference circuit in October, while also sharing new data around its lead program QTORIN rapamycin and broader rare dermatology pipeline, giving investors fresh information to evaluate.

On the market side, Palvella Therapeutics has seen its share price pull back over the past month, with a 30 day share price return of 16.35% and a 90 day share price return of 9.35%. This comes despite a year to date share price gain of 24.75% and a 1 year total shareholder return of 71.37%. This suggests that recent conference and data updates are being weighed against earlier enthusiasm as investors reassess both upside potential and risk around upcoming QTORIN milestones.

Spot emerging stories beyond Palvella Therapeutics by scanning a hand picked group of 21 high quality undiscovered gems, which, like PVLA, are pursuing high impact niches in their fields.

Bulls see Palvella Therapeutics as a rare dermatology platform at a steep implied discount, while bears focus on losses and binary QTORIN risk. Which side does today’s valuation lean toward as the evidence stacks up?

Most Popular Narrative: 45% Undervalued

On the most followed narrative, Palvella Therapeutics screens as materially undervalued, with a fair value estimate of $229 against a last close of $125.10. This puts the spotlight firmly on how QTORIN and the broader rare disease platform might justify that gap.

The first potential FDA approval for QTORIN rapamycin in microcystic lymphatic malformations, supported by positive Phase III SELVA data and a planned NDA filing in the second half of 2026, could open an initial revenue stream and begin to leverage existing operating costs as commercial infrastructure scales.

See why 1 investors see Palvella Therapeutics as 45% undervalued.

Result: Fair Value of $229 (UNDERVALUED)

Still, the bullish Palvella Therapeutics story hinges on QTORIN clearing FDA review on schedule and on physician uptake supporting the planned commercial build out.

Find out about the key risks to this Palvella Therapeutics narrative.

Next Steps

Conflicted by the mix of enthusiasm and caution around Palvella Therapeutics so far? Act while the information is fresh and weigh both sides for yourself with 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Palvella Therapeutics?

If Palvella Therapeutics has your attention, do not stop here. Broaden your watchlist now by scanning other focused opportunities using the Simply Wall Street Screener.

• Target resilient cash generators that still look unloved by the market by running a filter built around 27 high quality undervalued stocks.
• Protect your downside first and hunt for stability by screening for 30 resilient stocks with low risk scores that aim to keep surprises to a minimum.
• Go off the beaten path and track potential early stage winners before the crowd by scanning our hand picked 7 elite penny stocks with strong financials.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com